Ionis Pharmaceuticals Inc

The commercialization of AI-driven drug development continues to move forward. Insilico Medicine announced a partnership to build a generative biology foundation model focused on biologic design and target optimization. The 2026 European Society for Medical Oncology annual meeting will open from October 23 to 27, featuring 28 breakthrough clinical studies led by or deeply involving China, of which 4 were selected for oral presentation in the plenary session, accounting for one-third of the total. In the pharmaceutical segment, 29 late-breaking abstract trial drugs were originally developed or co-developed by domestic Chinese pharmaceutical companies, covering multiple frontier areas including antibody-drug conjugates, bispecific antibodies, and EGFR-TKI-resistant non-small cell lung cancer. Guosheng Securities noted that the radiopharmaceutical sector recently saw two major deals: Telix acquired ITM for 1.65 billion US dollars, and Borui Chuanghe signed a collaboration with Novartis worth up to 900 million US dollars. Meanwhile, Ionis' oligonucleotide therapy Ulefnersen met its primary endpoint in a Phase III study for FUS-ALS, providing the first effective treatment option for this rare disease. As of August 31, 2026, the top ten weighted stocks in the SSE STAR Market Biomedical Index accounted for 51.54% of the total, namely United Imaging Healthcare, BeiGene, Allist Pharmaceuticals, Baili Tianheng, Zelgen Biopharmaceuticals, RemeGen, iRay Technology, Huitai Medical, Junshi Biosciences, and MGI Tech.

Otsuka Pharmaceutical and U.S.-based Ionis Pharmaceuticals announced on the 22nd that their jointly developed treatment for hereditary amyotrophic lateral sclerosis, ulefnersen, met its primary goal in a late-stage clinical trial. In patients with FUS mutation ALS, a rare inherited form of ALS that damages the nerve cells controlling movement, ulefnersen improved function and extended survival compared with the placebo group. The drug reduced markers of nerve cell damage and slowed disease progression, and most side effects were mild or moderate, indicating a favorable safety profile. No approved treatment currently targets the genetic cause of FUS-ALS, and the two companies plan to discuss the results with the U.S. Food and Drug Administration and global health authorities as they explore a path toward accelerated approval. Separately, Otsuka Pharmaceutical has launched a global early access program for FUS-ALS patients unable to participate in the trial, allowing physicians to request access to ulefnersen before approval.

Roche Holding partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The clinical win comes on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date, and a 1-year total shareholder return of 44.02%. Roche Holding now trades at CHF363.20, only about 3% below the average analyst target, yet screens at a roughly 59% discount to an intrinsic value estimate, while the most followed narrative fair value of CHF353.34 pegs the stock as 2.8% overvalued. The SWS DCF model points the opposite way, implying a future cash flow value of CHF893.70. The story could still change quickly if key Phase 3 programs disappoint or if biosimilar pressure on older blockbusters accelerates faster than expected.

Ionis Pharmaceuticals announced positive late-stage results from two partnered phase III programs. The FUSION study of ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene met its primary endpoint assessing functional impairment and survival at 72 weeks, with Ionis reporting the results as statistically significant without disclosing supporting numbers; Otsuka Pharmaceutical, which holds worldwide commercialization rights licensed in 2024, plans to discuss the data with the FDA and other global health authorities regarding potential expedited regulatory submission pathways. Separately, the IMAgINATION study of sefaxersen in adults with primary immunoglobulin A nephropathy, conducted by Ionis' partner Roche, met its primary endpoint in a prespecified interim analysis, showing statistically significant and clinically meaningful reductions in proteinuria after 37 weeks, and will continue in a blinded manner to evaluate kidney function over two years with estimated glomerular filtration rate at week 105 as the longer-term measure. Roche licensed sefaxersen from Ionis in 2022 and is responsible for the phase III study and future global development, regulatory and commercialization activities, while Ionis is eligible for milestone payments and tiered royalties on net sales of both drugs. The two wins follow back-to-back cardiovascular setbacks for Ionis, including the phase III CARDIO-TTRansform failure of Wainua with AstraZeneca in July and the phase III Lp(a)HORIZON miss for pelacarsen with Novartis, and come after the FDA approval of Zanvastro for Alexander disease earlier this month. Year to date, Ionis shares have lost 42% compared with the industry's 2% decline.

Roche announced positive prespecified interim results from the ongoing phase III IMAgINATION study of investigational sefaxersen in adults with primary IgA nephropathy, with the study meeting its primary endpoint of statistically significant and clinically meaningful proteinuria reduction versus placebo at 37 weeks as measured by 24-hour urine protein-to-creatinine ratio. Sefaxersen is a once-monthly subcutaneous injection designed for self-administration that inhibits complement factor B production in the liver, and its safety and tolerability profile was consistent with previously reported data with no new safety signals. The IMAgINATION study enrolled 459 people randomized 1:1 to receive sefaxersen or placebo for 105 weeks and will continue blinded to evaluate change in kidney function over two years as measured by estimated glomerular filtration rate at week 105. Interim data will be presented at an upcoming medical congress and shared with health authorities. Roche licensed sefaxersen from Ionis for the treatment of complement mediated diseases.

Cathie Wood's Ark Invest added heavily to CoreWeave while cutting several other AI and technology positions last week. Ark bought about 239,000 shares of CoreWeave, the AI cloud infrastructure provider, worth roughly $24.7 million, and also added about $7.25 million of Meta Platforms shares. The purchases came alongside sales of about $5.9 million of Palantir, $10 million of Advanced Micro Devices, $13.1 million of Alphabet and $6.5 million of Shopify. Outside technology, Ark bought about $8.9 million of Ionis Pharmaceuticals and $9.3 million of Guardant Health while cutting $21.8 million of 10x Genomics. Its largest single sale was 1.53 million shares of the ARK 21Shares Bitcoin ETF, worth about $39.8 million, and it also reduced positions in Circle and Coinbase.

The U.S. FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen) as the first treatment for Alexander disease, a rare neurological disorder affecting fewer than 1,000 people in the U.S. The drug, designed to reduce abnormal GFAP protein production, showed statistically significant improvement in gait speed in a pivotal study and is approved for both pediatric and adult patients. Ionis plans to commercialize Zanvastro independently in the U.S., marking a key step in its strategy to launch wholly owned neurology medicines, while Recordati holds rights outside the U.S. Analysts at William Blair estimate peak annual sales of approximately $295 million, though the small patient population and complex administration may limit uptake. The approval validates Ionis' RNA-targeting platform and strengthens its neurology portfolio, which includes Spinraza, Wainua, and Qalsody.

Ionis Pharmaceuticals reported a narrower-than-expected adjusted loss and higher revenues for the second quarter of 2026, while reaffirming its full-year guidance. The company posted an adjusted loss of 43 cents per share, beating the Zacks Consensus Estimate of a loss of 89 cents, and revenues of $268 million, surpassing the $190.7 million estimate. Total revenues fell nearly 41% year over year due to a $280 million upfront payment from Ono Pharmaceutical in the prior-year period, but excluding that payment, revenues rose 56%. Ionis reiterated its 2026 revenue guidance of $875 million to $900 million, with Tryngolza net product sales expected between $100 million and $110 million and Dawnzera between $110 million and $120 million, and maintained its adjusted operating loss forecast of $425 million to $475 million.

Cathie Wood's ARK Genomic Revolution ETF has purchased $15.3 million worth of Ionis Pharmaceuticals shares since the beginning of July, following a sharp decline in the stock after a late-stage trial failure for eplontersen in ATTR-CM. The purchases came after Ionis and partner AstraZeneca announced the surprise setback, suggesting Wood is capitalizing on the drop while maintaining a long-term view. Ionis recently won FDA approval for Tryngolza to treat severe hypertriglyceridemia, expanding its target market to more than 3 million U.S. patients, and is pivoting to commercialize its own assets with peak sales guidance raised to $3 billion. The company reported first-quarter revenue of $246 million, up 86% year over year, and expects to reach cash flow break-even by 2028. Ionis also has late-stage pipeline catalysts including a priority review for zilganersen in Alexander disease and an upcoming phase 3 readout for pelacarsen partnered with Novartis.

Ionis Pharmaceuticals announced the completion of enrollment in Cohort 1 of the global Phase 3 REVEAL study evaluating obudanersen, an investigational RNA-targeted therapy for Angelman syndrome. The pivotal cohort enrolled 136 participants between the ages of 2 and under 18 with genetically confirmed UBE3A deletion or mutation. Enrollment in the adult cohort, which includes participants aged 18 to 50, is expected to conclude in the third quarter of 2026, with topline results from the REVEAL study anticipated in the second half of 2027. The trial was designed with input from the Angelman syndrome community to evaluate the therapy across a broad patient population. Separately, H.C. Wainwright raised its price target on Ionis to $130 from $125 and maintained a Buy rating following the FDA approval of Tryngolza.

TimesSquare Capital Management's U.S. Mid Cap Growth Strategy fell 7.72% net in the first quarter of 2026, underperforming the Russell Midcap Growth Index's decline of 6.35%. The strategy navigated geopolitical tensions, temporary global tariffs, and supply chain disruptions following U.S. and Israeli involvement in Iran, which prompted a shift to safer assets. Central banks maintained steady policies despite energy-driven inflation. The strategy added Ionis Pharmaceuticals, a commercial-stage biotechnology company focused on neurology and cardiovascular indications, citing several commercially approved drugs and a deep pipeline with important clinical trial readouts this year. Ionis reported total revenues of $246 million in the first quarter, an 87% year-over-year increase, and its shares gained 84.16% over the past 52 weeks.

Ionis Pharmaceuticals has signed an ex-U.S. licensing agreement with Recordati for zilganersen, an investigational RNA therapy for Alexander disease. The deal grants Recordati rights to commercialize zilganersen outside the United States, while Ionis retains U.S. rights and global development leadership. Ionis is set to receive upfront and milestone payments, plus potential royalties on ex-U.S. sales, as FDA review of zilganersen for Alexander disease continues.

Ionis Pharmaceuticals shares rose 9.5% after the FDA expanded the label for Tryngolza to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, moving beyond its initial approval for familial chylomicronemia syndrome. The approval makes Tryngolza the first and only therapy in the US with a label specifically addressing both triglyceride reduction and acute pancreatitis risk in this high-need population. The expanded indication opens a much broader market, though it also introduces pricing pressure and payer negotiation risks as Ionis shifts from a rare disease to a larger patient group. Ionis' investment narrative projects $2.3 billion in revenue and $300.8 million in earnings by 2029, with a fair value estimate of $100.92 per share, representing a 24% upside. The most bullish analysts see revenue reaching about $2.8 billion and earnings $456 million by 2029, but the broader label and pricing dynamics could either reinforce or challenge those targets.

This week brought a mix of FDA and EU approvals, layoffs, acquisitions, and clinical trial updates across the biotech sector. Ionis Pharmaceuticals secured FDA approval for TRYNGOLZA as an adjunct therapy for severe hypertriglyceridemia, while Merck received European Commission approval for Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. Gilead's Trodelvy was cleared by the FDA for first-line metastatic triple-negative breast cancer, and Pfizer's IBRANCE won expanded approval for HR+/HER2+ metastatic breast cancer. Natera gained Japanese approval for its Signatera MRD test in colorectal cancer, and AbbVie's MAVIRET was approved in the EU for both acute and chronic Hepatitis C. Achieve Life Sciences received an FDA Complete Response Letter for its Cytisinicline NDA due to manufacturing deficiencies, though no efficacy or safety issues were raised. ADC Therapeutics announced a 17% workforce reduction as part of a strategic reorganization to focus on its ZYNLONTA lymphoma franchise. In dealmaking, Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion, while Ionis inked a licensing deal with Recordati for Zilganersen, an investigational therapy for Alexander disease. Passage Bio and Remix Therapeutics entered an all-stock merger agreement, and Boundless Bio and Serapha Bio also announced an all-stock merger. On the clinical front, IMUNON's Phase 3 OVATION 3 trial passed a safety review, Takeda's Zasocitinib showed superiority over Deucravacitinib in a Phase 3 psoriasis study, and Eledon reported positive long-term kidney transplant data for Tegoprubart. However, Pfizer's Sigvotatug vedotin missed its primary overall survival endpoint in a Phase 3 non-small cell lung cancer study, and MapLight's ML-004 failed to meet its primary endpoint in autism spectrum disorder, though it showed an irritability signal in adolescents. Definium Therapeutics reported positive Phase 3 results for DT120 ODT in major depressive disorder.

The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' TRYNGOLZA as the first and only treatment indicated to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. TRYNGOLZA, available in 50 mg or 80 mg doses self-administered once monthly via an autoinjector, was approved based on Phase 3 CORE and CORE2 studies showing it lowered fasting triglyceride levels by up to 72% compared to placebo at six months and reduced acute pancreatitis events by up to 91%. Among patients with baseline and 12-month data, 86% achieved triglyceride levels below 500 mg/dL, a critical threshold for reducing acute pancreatitis risk. The number needed to treat over one year to prevent one episode of acute pancreatitis was 20 in the overall cohort and four in patients with triglycerides of at least 880 mg/dL and a prior history of acute pancreatitis. Ionis plans to launch TRYNGOLZA in the U.S. in July, marking its first independent commercial launch in a prevalent condition.

Deciphera Pharmaceuticals announced the first patient has been dosed in the global pivotal Phase 3 INTREPID study evaluating sapablursen for the treatment of polycythemia vera, a rare and potentially life-threatening hematologic disease. The study will compare the efficacy and safety of sapablursen to placebo over a 32-week double-blind treatment period followed by up to 124 weeks of open-label treatment, with the primary endpoint being response defined by the absence of phlebotomy eligibility. Sapablursen has received Fast Track, Orphan Drug, and Breakthrough Therapy designations from the U.S. Food and Drug Administration. The trial has initiated in the United States and is planned in additional regions including North America, Latin America, Asia Pacific, and Europe. Deciphera is a member of Ono Pharmaceutical, which obtained exclusive global rights to sapablursen through a license agreement with Ionis Pharmaceuticals in March 2025.